What is HC Wainwright’s Estimate for GRCE FY2025 Earnings?

Grace Therapeutics, Inc. (NASDAQ:GRCE) – Stock analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for shares of Grace Therapeutics in a report issued on Tuesday, February 18th. HC Wainwright analyst O. Livnat forecasts that the company will earn ($1.14) per share for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Grace Therapeutics’ current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Grace Therapeutics’ Q4 2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at $0.26 EPS and FY2029 earnings at $1.68 EPS.

Grace Therapeutics (NASDAQ:GRCE) last announced its quarterly earnings data on Thursday, February 13th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01.

Grace Therapeutics Trading Up 1.5 %

GRCE stock opened at $3.39 on Thursday. Grace Therapeutics has a 1 year low of $2.13 and a 1 year high of $4.97. The company has a 50 day moving average of $3.65. The stock has a market cap of $34.37 million, a price-to-earnings ratio of -2.92 and a beta of 1.36.

Grace Therapeutics Company Profile

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.